AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1699654 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms/m2 per day of rhG-CSF
Number of subjects: 16
Study 4397655 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 6
Study 4397655 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 4397655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31959224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored cognitive behavioural therapy (CBT) intervention
Number of subjects: 60
Study 31959224 — intervention group
Group type: COMPARATOR
Intervention: Supportive listening (SL) intervention
Number of subjects: 60
Study 31231865 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin (ATV) daily for a median of 27 days
Number of subjects: 158
Study 31231865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 28953118 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Loop Excision of the Transformation Zone (LLETZ)
Number of subjects: 172
Study 28953118 — intervention group
Group type: COMPARATOR
Intervention: True Cone Biopsy Electrode Excision (TCBEE)
Number of subjects: 172
Study 25609033 — intervention group
Group type: EXPERIMENTAL
Intervention: XP Bond adhesive with 15 seconds etching time in G1 (21-35 years)
Number of subjects: 40
Study 25609033 — intervention group
Group type: EXPERIMENTAL
Intervention: XP Bond adhesive with 30 seconds etching time in G1 (21-35 years)
Number of subjects: 40
Study 25609033 — intervention group
Group type: EXPERIMENTAL
Intervention: XP Bond adhesive with 15 seconds etching time in G2 (40-54 years)
Number of subjects: 40
Study 25609033 — intervention group
Group type: EXPERIMENTAL
Intervention: XP Bond adhesive with 30 seconds etching time in G2 (40-54 years)
Number of subjects: 40
Study 23122836 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Intralipid (IL) infusion
Number of subjects: 28
Study 23122836 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 28
Study 21604929 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme
Number of subjects: 30
Study 19566559 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured antenatal education (two 15‐min sessions)
Number of subjects: 100
Study 19566559 — intervention group
Group type: COMPARATOR
Intervention: Normal care (control group)
Number of subjects: 100
Study 19566559 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 19566559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 100
Study 19566559 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study 16231165 — intervention group
Group type: EXPERIMENTAL
Intervention: Video presentation before surgery
Number of subjects: 100
Study 16231165 — intervention group
Group type: COMPARATOR
Intervention: No video presentation (Control)
Number of subjects: 100
Study 14715353 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication
Number of subjects: 87
Study 11711768 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299V (LP299V) in liquid suspension
Number of subjects: 40
Study 11711768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9204357 — intervention group
Group type: EXPERIMENTAL
Intervention: iopentol (Imagopaque 300 mg I/ml)
Number of subjects: 129
Study 9204357 — intervention group
Group type: COMPARATOR
Intervention: amidotrizoate (Peritrast 300 mg I/ml)
Number of subjects: 129
Study 7953013 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral haloperidol
Number of subjects: 47
Study 7953013 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of oral haloperidol
Number of subjects: 47
Study 7953013 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of oral haloperidol
Number of subjects: 47
Study 7953013 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive lorazepam (for non-responders)
Number of subjects: 47
Study 3673203 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of 3 micrograms given at 0, 1 and 6 months
Number of subjects: 203
Study 3673203 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of 3 micrograms given at 0, 1 and 2 months
Number of subjects: 203
Study 3673203 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 203
Study 29720124 — intervention group
Group type: EXPERIMENTAL
Intervention: smalltalk program (group program only or group program with additional home coaching)
Number of subjects: 1226
Study 29720124 — intervention group
Group type: COMPARATOR
Intervention: standard/usual care (control)
Number of subjects: 1226
Study 28520577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil (Group SR)
Number of subjects: 0
Study 28520577 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-saline (Group SS)
Number of subjects: 0
Study 26402043 — intervention group
Group type: EXPERIMENTAL
Intervention: Depletion condition (self-regulatory resources reduced)
Number of subjects: 120
Study 26402043 — intervention group
Group type: COMPARATOR
Intervention: No-depletion condition (self-regulatory resources intact)
Number of subjects: 120
Study 26402043 — intervention group
Group type: EXPERIMENTAL
Intervention: Depletion condition with high trait self-control
Number of subjects: 120
Study 23664712 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant pharmacotherapy (three different regimens) for 12 weeks
Number of subjects: 96
Study 23664712 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed controls
Number of subjects: 96
Study 21615671 — intervention group
Group type: EXPERIMENTAL
Intervention: muraglitazar (MURA), 5 mg/day
Number of subjects: 27
Study 21615671 — intervention group
Group type: COMPARATOR
Intervention: placebo (PLAC)
Number of subjects: 27
Study 19560327 — intervention group
Group type: EXPERIMENTAL
Intervention: D-camphor-crataegus berry extract combination (Korodin)
Number of subjects: 80
Study 19560327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 16469981 — intervention group
Group type: EXPERIMENTAL
Intervention: High-isoflavone soy protein isolate (high-iso SPI; 61.7 ± 7.4 mg aglycone isoflavones/d)
Number of subjects: 35
Study 16469981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-isoflavone soy protein isolate (low-iso SPI; 1.64 ± 0.19 mg aglycone isoflavones/d)
Number of subjects: 35
Study 16469981 — intervention group
Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 35
Study 16138726 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐regulatory care
Number of subjects: 224
Study 16138726 — intervention group
Group type: COMPARATOR
Intervention: Routine nursery care (control)
Number of subjects: 224
Study 11693319 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy with standardized 3-month omeprazole treatment
Number of subjects: 151
Study 11693319 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standardized 3-month omeprazole treatment
Number of subjects: 151
Study 11693319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (H. pylori eradication and placebo)
Number of subjects: 151
Study 9135268 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 24
Study 9135268 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 24
Study 9135268 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 24
Study 9135268 — intervention group
Group type: COMPARATOR
Intervention: Right lateral position
Number of subjects: 24
Study 7968373 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients (AD)
Number of subjects: 5
Study 7968373 — intervention group
Group type: COMPARATOR
Intervention: Control brains
Number of subjects: 5
Study 3108171 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (20 mg daily)
Number of subjects: 24
Study 3108171 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (5 mg daily)
Number of subjects: 24
Study 28116581 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (serotonin reuptake inhibitor)
Number of subjects: 27
Study 28116581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 28116581 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (noradrenaline reuptake inhibitor)
Number of subjects: 27
Study 25945865 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol treatment (group A, n = 16)
Number of subjects: 36
Study 25945865 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group B, n = 20)
Number of subjects: 36
Study 25945865 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy children)
Number of subjects: 36
Study 23637276 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical shellac
Number of subjects: 26
Study 23637276 — intervention group
Group type: COMPARATOR
Intervention: 10% povidone-iodine (PVP-I) solution
Number of subjects: 26
Study 21525157 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg weekly
Number of subjects: 77
Study 21525157 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose transdermal testosterone replacement therapy
Number of subjects: 77
Study 21525157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Risedronate + Testosterone)
Number of subjects: 77
Study 21525157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 18972301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-powder inhaler
Number of subjects: 37
Study 18972301 — intervention group
Group type: COMPARATOR
Intervention: Pressurized metered-dose inhaler
Number of subjects: 37
Study 18972301 — intervention group
Group type: COMPARATOR
Intervention: Control groups (spacer and water gargle)
Number of subjects: 37
Study 16432268 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablet (ODT) administered sublingually
Number of subjects: 10
Study 16432268 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablet (ODT) administered normally
Number of subjects: 10
Study 16432268 — intervention group
Group type: COMPARATOR
Intervention: Standard oral tablet (SOT)
Number of subjects: 10
Study 12635388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 2 mg
Number of subjects: 118
Study 12635388 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 118
Study 12635388 — intervention group
Group type: COMPARATOR
Intervention: Dolasetron 12.5 mg
Number of subjects: 118
Study 12635388 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 118
Study 10963985 — intervention group
Group type: EXPERIMENTAL
Intervention: First episode schizophrenia (FES) group
Number of subjects: 20
Study 10963985 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 20
Study 8601566 — intervention group
Group type: EXPERIMENTAL
Intervention: MAB + MTX (methotrexate, 50 mg/m2/week)
Number of subjects: 53
Study 8601566 — intervention group
Group type: COMPARATOR
Intervention: MAB (orchiectomy followed by flutamide therapy)
Number of subjects: 53
Study 8601566 — intervention group
Group type: EXPERIMENTAL
Intervention: MAB + MTX
Number of subjects: 53
Study 8601566 — intervention group
Group type: COMPARATOR
Intervention: MAB
Number of subjects: 53
Study 1595921 — intervention group
Group type: EXPERIMENTAL
Intervention: Brandt Anesthesia Tube
Number of subjects: 48
Study 1595921 — intervention group
Group type: COMPARATOR
Intervention: Mallinckrodt endotracheal tube
Number of subjects: 48
Study 6430328 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lactose-free sodium cromoglycate powder (C)
Number of subjects: 30
Study 6430328 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 30
Study 31300595 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (5 mg)
Number of subjects: 120
Study 31300595 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (100 µg)
Number of subjects: 120
Study 31300595 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 120
Study 30347801 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMO) composition in breast milk
Number of subjects: 106
Study 30347801 — intervention group
Group type: EXPERIMENTAL
Intervention: 3′‐sialyllactose and 6′‐sialyllactose levels
Number of subjects: 106
Study 30347801 — intervention group
Group type: EXPERIMENTAL
Intervention: Various HMOs
Number of subjects: 106
Study 25868831 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 64589
Study 25868831 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 64589
Study 25868831 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 64589
Study 24046070 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IDH1 levels in patients with NSCLC
Number of subjects: 1422
Study 24046070 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH1 for lung adenocarcinoma diagnosis
Number of subjects: 1422
Study 24046070 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IDH1 with CEA, CA125, and Cyfra21‐1
Number of subjects: 1422
Study 24046070 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IDH1 levels
Number of subjects: 1422
Study 21460737 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional cross‐wiring technique
Number of subjects: 29
Study 21460737 — intervention group
Group type: COMPARATOR
Intervention: Lateral cross‐wiring technique
Number of subjects: 29
Study 19584895 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (6 g ALA from 30 g flaxseed oil)
Number of subjects: 2
Study 19584895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground flaxseed (6 g ALA from 30 g ground flaxseed)
Number of subjects: 2
Study 19584895 — intervention group
Group type: COMPARATOR
Intervention: Control (no flaxseed intervention)
Number of subjects: 2
Study 19584895 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed supplementation
Number of subjects: 2
Study 17416366 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based personal health record
Number of subjects: 180
Study 17416366 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 180
Study 15029102 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (1 mg x 2/die)
Number of subjects: 14
Study 15029102 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (2 mg/die)
Number of subjects: 14
Study 11499122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 719
Study 11499122 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 719
Study 9876888 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic needle (22-gauge)
Number of subjects: 99
Study 9876888 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle (20-gauge)
Number of subjects: 99
Study 9198495 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-weighted turbo spin echo (T2-TSE)
Number of subjects: 21
Study 9198495 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced T1-weighted SE sequences with fat-suppression
Number of subjects: 21
Study 9198495 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced fat-suppressed T1-weighted SE
Number of subjects: 21
Study 9198495 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced T1-weighted SE
Number of subjects: 21
Study 9198495 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced T1-weighted SE
Number of subjects: 21
Study 1770553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg/d)
Number of subjects: 7
Study 1770553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7037160 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation
Number of subjects: 0
Study 29124388 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive pomace-enriched biscuit (OEP)
Number of subjects: 62
Study 29124388 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic control (CTRL)
Number of subjects: 62
Study 29168028 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic administration of steroids (prednisolone intravenously followed by methylprednisolone orally)
Number of subjects: 102
Study 29168028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic administration of methylprednisolone
Number of subjects: 102
Study 29168028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of systemic and intratympanic steroids
Number of subjects: 102
Study 29168028 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified as a separate group)
Number of subjects: 102
Study 29168028 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients (under 60 years old)
Number of subjects: 102
Study 27482008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 11145
Study 27482008 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 11145
Study 24485548 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of MMRV
Number of subjects: 5803
Study 24485548 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR at dose one and monovalent varicella vaccine at dose two (MMR+V group)
Number of subjects: 5803
Study 24485548 — intervention group
Group type: COMPARATOR
Intervention: Two doses of MMR (control group)
Number of subjects: 5803
Study 22077187 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) with mothers
Number of subjects: 37
Study 22077187 — intervention group
Group type: COMPARATOR
Intervention: Skin-to-skin contact (SSC) with fathers
Number of subjects: 37
Study 22077187 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) with either parent
Number of subjects: 37
Study 22077187 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with mothers
Number of subjects: 37
Study 22077187 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with fathers
Number of subjects: 37
Study 20923288 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (performance feedback, small-group teaching seminars, and posters)
Number of subjects: 7901
Study 20923288 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 7901
Study 20923288 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 7901
Study 18600386 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day triple therapy (amoxicillin, clarithromycin, proton pump inhibitor)
Number of subjects: 275
Study 18600386 — intervention group
Group type: COMPARATOR
Intervention: 7-day triple therapy (amoxicillin, clarithromycin, proton pump inhibitor)
Number of subjects: 275
Study 18600386 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (omeprazole, bismuth subcitrate, doxycycline, metronidazole)
Number of subjects: 275
Study 18600386 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after quadruple therapy
Number of subjects: 275
Study 16077384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenosides compound (1.35 mg/kg intravenously before and throughout cardiopulmonary bypass)
Number of subjects: 24
Study 16077384 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study 11836266 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg/d plus KCl placebo)
Number of subjects: 9
Study 11836266 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ; 25 mg plus 20 mmol KCl/d)
Number of subjects: 9
Study 9709845 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hip joints
Number of subjects: 161
Study 9709845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetabular dysplastic hip joints
Number of subjects: 161
Study 9709845 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational acetabular osteotomy (RAO)
Number of subjects: 161
Study 7836249 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 100
Study 7836249 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 100
Study 7836249 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 100
Study 7836249 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct PTCA to left anterior descending artery
Number of subjects: 100
Study 2901566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ditiocarb sodium ('Imuthiol') 10 mg/kg body weight given orally once a week
Number of subjects: 83
Study 2901566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 2901566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ditiocarb sodium ('Imuthiol')
Number of subjects: 83
Study 31738283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (5 ml of 30% dextrose, 4 ml of saline, and 1 ml of 2% lidocaine mixture)
Number of subjects: 30
Study 31738283 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 ml of saline and 1 ml of 2% lidocaine mixture)
Number of subjects: 30
Study 29154813 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 1230
Study 29154813 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 1230
Study 26946985 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg/d
Number of subjects: 147
Study 26946985 — intervention group
Group type: COMPARATOR
Intervention: Control arm (erlotinib alone 150 mg/d)
Number of subjects: 147
Study 23892583 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 107
Study 23892583 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 107
Study 23892583 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Exercise
Number of subjects: 107
Study 23892583 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 107
Study 22538152 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm needle with 20 U insulin diluent
Number of subjects: 56
Study 22538152 — intervention group
Group type: COMPARATOR
Intervention: 8 mm needle with 20 U insulin diluent
Number of subjects: 56
Study 22538152 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm needle with 60 U insulin diluent
Number of subjects: 56